Replimune Group (REPL)
(Delayed Data from NSDQ)
$11.06 USD
+0.25 (2.31%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $11.06 0.00 (0.00%) 5:44 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 81 - 100 ( 196 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
MASTERKEY-265 Disappointing, but Read-Through to REPL Limited
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q1; Full Enrollment for Registration-Directed Programs Expected Mid:2022
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: The Next 12 Months Could be Transformational for the Platform
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Updated RP1 and RP2 Clinical Results; FY2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Data Updates for RP1 and RP2; Liver Mets Program Announced
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q4 Financials; Clinical Updates Ahead at Investor Event
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
FY2021 Results. Important to Watch Clinical Updates in June.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Regulatory Updates for RP1 in CSCC and PD-1-Refractory Melanoma
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department